Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study
Cancer is a leading cause of death worldwide. It is estimated that approximately 55,000 Canadians are surviving with brain tumors. It is projected that around 3000 persons will be diagnosed with brain and spinal cord tumors, and approximately 75 percent patients will not survive. Out of all brain cancers, high-grade gl
| Condition(s) | Anesthesia, Brain Cancer, Survival |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Cancer is a leading cause of death worldwide. It is estimated that approximately 55,000 Canadians are surviving with brain tumors. It is projected that around 3000 persons will be diagnosed with brain and spinal cord tumors, and approximately 75 percent patients will not survive. Out of all brain cancers, high-grade gliomas \[Glioblastoma Multiforme (GBM)\] impose highest morbidity and mortality. Therefore, it is important to explore ways in which Investigators can improve and prolong the lives of patients suffering from brain cancers, particularly high-grade glioma, which is the most common and aggressive primary brain tumor. So far the Investigators know that the surgery, chemotherapy and radiotherapy are the three corner stones management options for these patients, and majority of the |
| Who can participate | Inclusion Criteria: 1. Patient presenting between Jul 1, 2022 and Dec 28, 2023 for elective procedure 2. Males or females of \>18 years 3. Patient will be undergoing primary craniotomy (with general anesthesia) for suspected high-grade primary glial brain tumor (WHO grade III and IV) Exclusion Criteria: 1. Patients of pediatric age group and pregnant patients 2. Patients previously diagnosed with severe adrenal dysfunction (over activity or insufficiency) 3. Suspected low grade (grade I, II), glioma, tumors involving brainstem and optic tract, and as well as non-glial tumors (i.e. suspected brain metastasis) 4. Awake craniotomies 5. Any conditions that preclude postoperative MRI 6. Motor evoked potential monitoring or any other intraoperative condition that renders choice of anesthetics af |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Health Network, Toronto |
| Locations | Toronto, Ontario, Canada |
| Start date | 2022-01-01 |
| NCT ID | NCT04962672 |
| Official listing | https://clinicaltrials.gov/study/NCT04962672 |